456 related articles for article (PubMed ID: 34062070)
1. The role of AMPK/mTOR signaling pathway in anticancer activity of metformin.
Chomanicova N; Gazova A; Adamickova A; Valaskova S; Kyselovic J
Physiol Res; 2021 Aug; 70(4):501-508. PubMed ID: 34062070
[TBL] [Abstract][Full Text] [Related]
2. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
3. Mechanism and application of metformin in kidney diseases: An update.
Song A; Zhang C; Meng X
Biomed Pharmacother; 2021 Jun; 138():111454. PubMed ID: 33714781
[TBL] [Abstract][Full Text] [Related]
4. Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR/AKT signaling.
Lu CC; Chiang JH; Tsai FJ; Hsu YM; Juan YN; Yang JS; Chiu HY
Int J Oncol; 2019 Apr; 54(4):1271-1281. PubMed ID: 30720062
[TBL] [Abstract][Full Text] [Related]
5. Metformin and cancer.
Vallianou NG; Evangelopoulos A; Kazazis C
Rev Diabet Stud; 2013; 10(4):228-35. PubMed ID: 24841876
[TBL] [Abstract][Full Text] [Related]
6. Update on the Protective Renal Effects of Metformin in Diabetic Nephropathy.
Eisenreich A; Leppert U
Curr Med Chem; 2017; 24(31):3397-3412. PubMed ID: 28393693
[TBL] [Abstract][Full Text] [Related]
7. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
8. Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells.
Cai H; Zhang Y; Han TK; Everett RS; Thakker DR
Int J Cancer; 2016 May; 138(9):2281-92. PubMed ID: 26669511
[TBL] [Abstract][Full Text] [Related]
9. Metformin suppresses the esophageal carcinogenesis in rats treated with NMBzA through inhibiting AMPK/mTOR signaling pathway.
Fan H; Yu X; Zou Z; Zheng W; Deng X; Guo L; Jiang W; Zhan Q; Lu SH
Carcinogenesis; 2019 Jul; 40(5):669-679. PubMed ID: 30445633
[TBL] [Abstract][Full Text] [Related]
10. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
11. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner.
Rattan R; Giri S; Hartmann LC; Shridhar V
J Cell Mol Med; 2011 Jan; 15(1):166-78. PubMed ID: 19874425
[TBL] [Abstract][Full Text] [Related]
12. Full title: High glucose protects mesenchymal stem cells from metformin-induced apoptosis through the AMPK-mediated mTOR pathway.
He X; Yang Y; Yao MW; Ren TT; Guo W; Li L; Xu X
Sci Rep; 2019 Nov; 9(1):17764. PubMed ID: 31780804
[TBL] [Abstract][Full Text] [Related]
13. Metformin and neoplasia: implications and indications.
Aljada A; Mousa SA
Pharmacol Ther; 2012 Jan; 133(1):108-15. PubMed ID: 21924289
[TBL] [Abstract][Full Text] [Related]
14. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology.
Green AS; Chapuis N; Lacombe C; Mayeux P; Bouscary D; Tamburini J
Cell Cycle; 2011 Jul; 10(13):2115-20. PubMed ID: 21572254
[TBL] [Abstract][Full Text] [Related]
15. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.
Shi WY; Xiao D; Wang L; Dong LH; Yan ZX; Shen ZX; Chen SJ; Chen Y; Zhao WL
Cell Death Dis; 2012 Mar; 3(3):e275. PubMed ID: 22378068
[TBL] [Abstract][Full Text] [Related]
17. Metformin: taking away the candy for cancer?
Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
[TBL] [Abstract][Full Text] [Related]
18. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.
Guo Q; Liu Z; Jiang L; Liu M; Ma J; Yang C; Han L; Nan K; Liang X
Mol Med Rep; 2016 Mar; 13(3):2590-6. PubMed ID: 26847819
[TBL] [Abstract][Full Text] [Related]
19. Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer.
Cai D; Sun H; Qi Y; Zhao X; Feng M; Wu X
Int J Gynecol Cancer; 2016 Nov; 26(9):1667-1672. PubMed ID: 27654259
[TBL] [Abstract][Full Text] [Related]
20. Metformin protects rat hepatocytes against bile acid-induced apoptosis.
Woudenberg-Vrenken TE; Conde de la Rosa L; Buist-Homan M; Faber KN; Moshage H
PLoS One; 2013; 8(8):e71773. PubMed ID: 23951244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
